RIGI and neoplasm: Accordingly, phaseI/II clinical study was performed to evaluate the safety, tolerability, and anti-tumor activity of intratumoral (IT)/intralesional (IL) injections of the agonist of RIG-I, MK-4621 (RGT100), as monotherapy or in combination with pembrolizumab in participants with advanced solid tumors (NCT03065023 and NCT03739138, summarized in Table 2).